FDA approves Lilly oral GLP-1 Foundayo as price war with Novo opens
Lilly will sell orforglipron through LillyDirect from $149 a month at the 0.8 mg starting dose, rising to $349 at the highest doses.
MH
By Maren Holt · Senior Reporter, GLP-1
Apr 5 03:00 ETSource: Genetic Engineering and Biotechnology News
The wire
- 01The FDA authorized Foundayo (orforglipron), a small-molecule oral GLP-1 receptor agonist for obesity; Lilly shares rose 4% to $954.52 on the news then fell 2% the next day.
- 02Cash-pay pricing runs $149 to $349 per month by dose, with high-dose patients getting $299 if they refill within 45 days, and $25 monthly out-of-pocket for many commercially insured patients.
- 03Novo's oral Wegovy 25 mg reached 577,000 total prescriptions with 52,000 filled in the week ending March 20; an analyst noted the approval was for a tablet, not the capsule used in Phase III.
From the source
Read at genengnews.comStockWatch: Price War Dampens Lilly Surge After Oral GLP-1 Wins FDA Nod
Eli Lilly researchers at work. Lilly won the approval it sought when the FDA authorized the company’s oral obesity drug Foundayo™ (orforglipron), but the pharma giant’s post-approval stock bounce was short lived as investors appeared divided on how quickly Lilly will be able to generate sales this year for the small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. [Eli Lilly]